COMPASS THERAPEUTICS, INC. (CMPX) Cash and securities
- Total cash · latest quarter (USD): Value $179.88M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $179.88M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $35.45M + $144.43M ≈ $179.88M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 35.45M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 144.43M USD | Marketable Securities, Current |
| Cash and current securities | 179.88M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $179.88M | (m) | $35.45M | $144.43M | (m) |
| 2026-03-31 | $194.69M | (m) | $55.17M | $139.52M | (m) |
| 2025-12-31 | $208.91M | (m) | $30.64M | $178.26M | (m) |
| 2025-09-30 | $219.90M | (m) | $46.21M | $173.68M | (m) |
| 2025-06-30 | $100.95M | (m) | $22.86M | $78.09M | (m) |
| 2025-03-31 | $112.64M | (m) | $41.05M | $71.59M | (m) |
| 2024-12-31 | $126.72M | (m) | $43.48M | $83.24M | (m) |
| 2024-09-30 | $135.40M | (m) | $36.80M | $98.60M | (m) |
| 2024-06-30 | $146.23M | (m) | $19.40M | $126.82M | (m) |
| 2024-03-31 | $156.25M | (m) | $23.67M | $132.58M | (m) |
| 2023-12-31 | $152.46M | (m) | $24.23M | $128.23M | (m) |
| 2023-09-30 | $163.70M | (m) | $30.43M | $133.28M | (m) |
| 2023-06-30 | $168.75M | (m) | $19.28M | $149.47M | (m) |
| 2023-03-31 | $175.17M | (m) | $27.03M | $148.14M | (m) |
| 2022-12-31 | $186.61M | (m) | $34.95M | $151.66M | (m) |
| 2022-09-30 | $120.60M | (m) | $16.48M | $104.12M | (m) |
| 2022-06-30 | $132.02M | (m) | $26.24M | $105.78M | (m) |
| 2022-03-31 | (m) | (m) | $136.38M | (m) | (m) |
| 2021-12-31 | (m) | (m) | $144.51M | (m) | (m) |
| 2021-09-30 | (m) | (m) | $25.51M | (m) | (m) |
| 2021-06-30 | (m) | (m) | $31.21M | (m) | (m) |
| 2021-03-31 | (m) | (m) | $39.70M | (m) | (m) |
| 2020-12-31 | (m) | (m) | $47.08M | (m) | (m) |
| 2020-09-30 | (m) | (m) | $55.52M | (m) | (m) |
| 2020-06-30 | (m) | (m) | $65.37M | (m) | (m) |
| 2020-03-31 | (m) | (m) | $3.75K | (m) | (m) |
| 2019-12-31 | (m) | (m) | $1.14K | (m) | (m) |
| 2019-09-30 | (m) | (m) | $882.00 | (m) | (m) |
| 2019-06-30 | (m) | (m) | $4.87K | (m) | (m) |
| 2019-03-31 | (m) | (m) | $4.87K | (m) | (m) |
| 2018-12-31 | (m) | (m) | $4.68K | (m) | (m) |
| 2018-09-30 | (m) | (m) | $2.45K | (m) | (m) |
| 2018-06-30 | (m) | (m) | $7.23K | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |